A Multicenter Randomized Open-label Study of Chidamide Plus HD-DEX Versus HD-DEX in ITP
Status:
Not yet recruiting
Trial end date:
2024-10-30
Target enrollment:
Participant gender:
Summary
Recently, histone deacetylase inhibitors (HDACi) has been used for their anti-inflammatory
and immunomodulatory activities. It has been shown that HDACi can alleviate graft-versus-host
disease by enhancing the number and function of Foxp3+ Tregs. Our group found that low-dose
HDACi alleviated thrombocytopenia in both passive and active murine models of ITP.
Furthermore, low-dose HDACi attenuated macrophage phagocytosis of antibody-coated platelets,
stimulated production of natural Foxp3+ Tregs, promoted peripheral conversion of T cells into
Tregs, and restored Treg suppressive function in vivo and in vitro. The project was
undertaking by Qilu Hospital of Shandong University and other 10 well-known hospitals in
China. In order to report the efficacy and safety of the low dose chidamide combined with
high-dose dexamethasone versus high-dose dexamethasone in the management of ITP.